Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

Papadopoulos Kyriakos P.; Tabernero Josep; Markman Ben; Patnaik Amita; Tolcher Anthony W.; Baselga Jose; Shi Weiliang; Egile Coumaran; Ruiz-Soto Rodrigo; Laird A. Douglas; Miles Dale; LoRusso Patricia M.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

【24h】

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

机译：SAR245409（XL765）（一种新型的口服PI3K / mTOR抑制剂）在晚期实体瘤患者中的一期安全性，药代动力学和药效动力学研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: This phase I, first-in-human study evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of SAR245409, an inhibitor of pan-Class I phosphoinositide 3-kinase (PI3K) and mTOR, administered orally once or twice daily in patients with advanced solid tumors.

机译：目的：这项第一阶段的首次人体研究评估了泛I类磷酸肌醇3激酶（PI3K）和mTOR抑制剂SAR245409的安全性，最大耐受剂量（MTD），药代动力学，药效学和初步疗效。晚期实体瘤患者每天口服一次或两次。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2014年第9期|共12页
作者
Papadopoulos Kyriakos P.; Tabernero Josep; Markman Ben; Patnaik Amita; Tolcher Anthony W.; Baselga Jose; Shi Weiliang; Egile Coumaran; Ruiz-Soto Rodrigo; Laird A. Douglas; Miles Dale; LoRusso Patricia M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors [J] . Papadopoulos Kyriakos P., Tabernero Josep, Markman Ben, Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第9期

机译：SAR245409（XL765）（一种新型的口服PI3K / mTOR抑制剂）在晚期实体瘤患者中的一期安全性，药代动力学和药效动力学研究
2. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors [J] . J?nneP.A., CohenR.B., LairdA.D., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2014,第3期

机译：PI3K / mTOR抑制剂SAR245409（XL765）联合厄洛替尼治疗晚期实体瘤的I期安全性和药代动力学研究
3. 218 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors [J] . E.Calvo, G.Edelman, J.Baselga, European Journal of Cancer Supplements . 2008,第12期

机译：218海报A阶段I剂量递增研究XL147（一种新型PI3K抑制剂，对晚期实体瘤患者口服）的安全性，药代动力学和药效学
4. Combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells. [C] . Fateye, Babasola, Chen Bin Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy XX . 2011

机译：内皮细胞和肿瘤细胞中PI3K / Akt / mTOR抑制剂和PDT的组合。
5. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-Clinical Mechanistic Assessment [D] . Moorthy, Ganesh P. 2015

机译：BEZ235，PI3K / mTOR抑制剂和依维莫司，mTOR抑制剂的新型组合的临床药代动力学：I期临床研究和非临床机制评估
6. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409 XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma [O] . Patrick Y. Wen, Antonio Omuro, Manmeet S. Ahluwalia, 2015

机译：PI3K / mTOR抑制剂voxtalisib（SAR245409XL765）加上替莫唑胺在放疗或不放疗中对高级别神经胶质瘤患者进行的I期剂量递增研究
7. Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors [O] . Jänne Pasi A., Cohen Roger B., Laird A. Douglas, 2014

机译：PI3K / mTOR抑制剂SAR245409（XL765）与厄洛替尼联合治疗晚期实体瘤的I期安全性和药代动力学研究

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

摘要

著录项

相似文献

相关主题

期刊订阅